TempraMed Technologies (FRA:9DY) Notes Receivable: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9DY TempraMed Technologies Ltd FRA:9DY
12 GF Score
Price €0.32
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies Notes Receivable?

TempraMed Technologies FRA:9DY +0.63% 12 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

TempraMed Technologies's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

TempraMed Technologies Notes Receivable Related Terms

TempraMed Technologies Notes Receivable Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Notes Receivable Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:9DY
12GF Score
TempraMed Technologies Ltd FRA:9DY
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
TempraMed Technologies (FRA:9DY) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on TempraMed Technologies and its competitors.
Is TempraMed Technologies' Notes Receivable too high?
TempraMed Technologies' current Notes Receivable is €0.00 Mil. Overall, TempraMed Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' Notes Receivable compare to ABT and SYK?
TempraMed Technologies' Notes Receivable of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on TempraMed Technologies and its competitors. TempraMed Technologies's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. TempraMed Technologies' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
12GF Score

Get the complete analysis for FRA:9DY

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price